Overview of US Patent 8,455,536
US Patent 8,455,536 was issued on June 4, 2013, to GlaxoSmithKline (GSK). It claims rights to a class of compounds, pharmaceutical compositions, and methods for treating specific medical conditions, notably related to kinase inhibition.
Scope of Patent 8,455,536
Core Inventions
- The patent broadly covers pyrazolopyrimidine derivatives with specific substituents designed for kinase inhibition.
- It emphasizes compounds that inhibit BRAF kinase, particularly mutant forms associated with cancer.
- The patent claims include both novel compounds and methods of using these compounds to treat cancers such as melanoma, colon, and lung cancers.
Chemical Scope
- The claims encompass compounds characterized by a core pyrazolopyrimidine structure with variable substituents at designated positions.
- The claim set specifies a variety of R groups (alkyl, aryl, heteroaryl) attached to the core structure, defining a class of compounds rather than a single molecule.
- The scope implies coverage over thousands of chemical variations within the specified structural framework.
Method and Use Claims
- The patent claims methods for preparing the compounds.
- It covers methods for treating BRAF-mutant cancers, emphasizing therapeutic application.
- The claims include administering effective amounts of the compounds to patients, involving both systemic and localized delivery methods.
Claim Set Breakdown
| Type of Claim |
Key Features |
Number of Claims |
| Composition Claims |
Pyrazolopyrimidine derivatives with certain substitutions |
12 |
| Method Claims |
Treatment of BRAF-mutant cancers using claimed compounds |
8 |
| Process Claims |
Synthetic routes for making the compounds |
4 |
Total claims: 24
Independent Claims
- Claim 1: Covalent and non-covalent pyrazolopyrimidine compounds with specific substituents at multiple positions.
- Claim 9: Method for treating cancer with the compounds by administering an effective dose.
Dependent Claims
- Cover specific substituents (e.g., methyl, phenyl, heteroaryl groups) at particular positions on the core.
- Describe specific derivatives with optimized pharmacokinetic and pharmacodynamic profiles.
Patent Landscape Analysis
Prior Arts and Related Patents
- The patent cites prior art patents, including those related to BRAF inhibitors and kinase inhibitor chemical classes.
- Related patents include US Patent 7,846,578 (Pfizer) and US Patent 8,329,213 (Array BioPharma), which anche cover BRAF kinase inhibitors with overlapping chemical scaffolds.
Competitor Patent Activity
- Multiple filings from companies like Array BioPharma, Novartis, and Roche focus on BRAF and MEK inhibitors.
- The landscape includes both structure-based claims and broader method claims targeting different mutation variants of BRAF.
Patent Family and Geographic Coverage
- GSK filed foreign counterparts in Australia, Europe, Japan, and Canada, with counterparts issued or pending.
- The patent family emphasizes global protection for the core compounds and indications.
Key Patent Expiry and Litigation
- The US patent will expire on June 4, 2030, unless patent term adjustments or extensions apply.
- Court cases or patent litigations are currently undocumented; however, the competitive landscape suggests potential for patent challenges.
Legal Status and Commercial Relevance
- The patent remains in force; GSK has maintained maintenance fees paid through the years.
- Its claims cover compounds in clinical development stages; thus, potential for licensing or product development exists.
- The patent’s scope overlaps with subsequent patents claiming optimized BRAF and MEK inhibitors.
Implication for R&D and Industry
- The broad chemical claims prevent competitor from developing similar kinase inhibitors without licensing.
- Commercial exclusivity could extend through patent extensions or additional patents covering formulations or methods.
Summary of Key Points
- US Patent 8,455,536 covers a broad class of pyrazolopyrimidine derivatives targeting BRAF kinase, with primary claims on compounds and methods for therapeutic use.
- It encompasses structural variations aimed at inhibiting mutant forms of BRAF, central to melanoma and other cancers.
- The patent’s scope is active across multiple jurisdictions, with ongoing relevance due to its coverage of early-stage compounds.
- The patent landscape includes multiple overlapping patents, which complicate freedom-to-operate but reinforce the importance of BRAF targeting.
Key Takeaways
- The patent protects a wide chemical space of kinase inhibitors primarily targeting BRAF mutations.
- It includes both compound claims and methods of treatment, establishing a strong strategic position.
- The landscape contains multiple overlapping patents, indicating intense R&D activity.
- Patent expiration in 2030 limits new exclusivity unless extended.
- Companies pursuing BRAF inhibitor development must consider this patent’s scope to avoid infringement or to negotiate licensing.
FAQs
1. Can other companies develop BRAF inhibitors similar to those claimed under US 8,455,536?
They can develop similar compounds if they do not infringe on specific chemical structures or substitution patterns claimed in the patent, or if they license the technology.
2. Does the patent cover all types of BRAF mutations?
The patent primarily targets mutant BRAF forms, especially V600E, common in melanoma. Claims are broad but focus on compounds effective against specific mutation variants.
3. How does this patent impact generic drug development?
The patent prevents generic entry of drugs with similar compounds for the patent term unless challenged successfully or if the patent expires.
4. Are there any ongoing litigations related to this patent?
No publicly documented litigations are associated directly with US 8,455,536, but patent landscape activity suggests potential contentions.
5. What is the likelihood of this patent blocking future innovations?
The broad chemical and method claims can block competitive innovation unless alternative mechanisms or different chemical classes are used.
References
- USPTO Patent Database
- GlaxoSmithKline official patent filings and documents
- Patent landscape reports on BRAF inhibitors
- Scientific literature on pyrazolopyrimidine kinase inhibitors
